Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Clifford

Showing results (31-40 of 209) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|September 27, 2023
Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?Bruce J Brew, David B Clifford
Journal of Neurovirology|March 17, 2006
Neurologic consequences of hepatitis C and human immunodeficiency virus coinfectionDavid B Clifford, Yijun Yang, Scott Evans
Journal of Neurovirology|April 24, 2003
The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminologyPaola Cinque, Igor J Koralnik, David B Clifford
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 14, 2020
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune RestorationS Richard Dunham, Robert Schmidt, David B Clifford
The Lancet. Neurology|April 17, 2018
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learnedEugene O Major, Tarek A Yousry, David B Clifford
Neurology|May 11, 2005
Atypical PML leading to a diagnosis of common variable immunodeficiencyMichael D Snyder, Gregory A Storch, David B Clifford
Nature Clinical Practice. Neurology|August 3, 2007
HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversityNed Sacktor, Noeline Nakasujja, Kevin Robertson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2016
A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?David B Clifford, Tarek A Yousry, Eugene O Major
AIDS (London, England)|October 28, 2005
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjectsDavid B Clifford, Scott R Evans, Yijun Yang, et al.
Neurology. Clinical Practice|August 15, 2018
Progressive multifocal leukoencephalopathy with extended natalizumab dosingLaura E Baldassari, Stephen E Jones, David B Clifford, et al.
Pageof 21

Showing results (31-40 of 209) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|September 27, 2023
Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?Bruce J Brew, David B Clifford
Journal of Neurovirology|March 17, 2006
Neurologic consequences of hepatitis C and human immunodeficiency virus coinfectionDavid B Clifford, Yijun Yang, Scott Evans
Journal of Neurovirology|April 24, 2003
The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminologyPaola Cinque, Igor J Koralnik, David B Clifford
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 14, 2020
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune RestorationS Richard Dunham, Robert Schmidt, David B Clifford
The Lancet. Neurology|April 17, 2018
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learnedEugene O Major, Tarek A Yousry, David B Clifford
Neurology|May 11, 2005
Atypical PML leading to a diagnosis of common variable immunodeficiencyMichael D Snyder, Gregory A Storch, David B Clifford
Nature Clinical Practice. Neurology|August 3, 2007
HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversityNed Sacktor, Noeline Nakasujja, Kevin Robertson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2016
A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?David B Clifford, Tarek A Yousry, Eugene O Major
AIDS (London, England)|October 28, 2005
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjectsDavid B Clifford, Scott R Evans, Yijun Yang, et al.
Neurology. Clinical Practice|August 15, 2018
Progressive multifocal leukoencephalopathy with extended natalizumab dosingLaura E Baldassari, Stephen E Jones, David B Clifford, et al.
Pageof 21